Effect of Nintedanib Nanothermoreversible Hydrogel on Neovascularization in an Ocular Alkali Burn Rat Model

References

• Chuang YL, Fang HW, Ajitsaria A, Chen KH, Su CY, Liu GS, Tseng CL. Development of Kaempferol-Loaded Gelatin Nanoparticles for the Treatment of Corneal Neovascularization in Mice. Pharmaceutics. 2019;11(12):635. doi:10.3390/pharmaceutics11120635.
   PubMed Web of Science ®Google Scholar
• Griffith GL, Wirostko B, Lee HK, Cornell LE, McDaniel JS, Zamora DO, Johnson AJ. Treatment of corneal chemical alkali burns with a crosslinked thiolated hyaluronic acid film. Burns. 2018;44(5):1179–1186. doi:10.1016/j.burns.2018.01.016.
   PubMed Web of Science ®Google Scholar
• Hakami NY, Dusting GJ, Chan EC, Shah MH, Peshavariya HM. Wound healing after alkali burn injury of the cornea involves Nox4-type NADPH oxidase. Invest Ophthalmol Vis Sci. 2020;61(12):20. doi:10.1167/iovs.61.12.20.
   PubMed Web of Science ®Google Scholar
• Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43(3):245–269. doi:10.1016/S0039-6257(98)00035-6.
   PubMed Web of Science ®Google Scholar
• Abdelfattah NS, Amgad M, Zayed AA, Salem H, Elkhanany AE, Hussein H, Abd El-Baky N. Clinical correlates of common corneal neovascular diseases: a literature review. Int J Ophthalmol. 2015;8(1):182–193. doi:10.3980/j.issn.2222-3959.2015.01.32.
   PubMed Web of Science ®Google Scholar
• Phillips K, Arffa R, Cintron C, Rose J, Miller D, Kublin CL, Kenyon KR. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol. 1983;101(4):640–643. doi:10.1001/archopht.1983.01040010640024.
   PubMedGoogle Scholar
• Maddula S, Davis DK, Maddula S, Burrow MK, Ambati BK. Horizons in therapy for corneal angiogenesis. Ophthalmology. 2011;118(3):591–599. doi:10.1016/j.ophtha.2011.01.041.
   PubMed Web of Science ®Google Scholar
• Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, Tuft SJ. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. Br J Ophthalmol. 2013;97(1):28–32. doi:10.1136/bjophthalmol-2012-302137.
   PubMed Web of Science ®Google Scholar
• Reed JW, Fromer C, Klintworth GK. Induced corneal vascularization remission with argon laser therapy. Arch Ophthalmol. 1975;93(10):1017–1019. doi:10.1001/archopht.1975.01010020797012.
   PubMedGoogle Scholar
• Gomer CJ, Ferrario A, Hayashi N, Rucker N, Szirth BC, Murphree AL. Molecular, cellular, and tissue responses following photodynamic therapy. Lasers Surg Med. 1988;8(5):450–463. doi:10.1002/lsm.1900080503.
   PubMed Web of Science ®Google Scholar
• Bachmann B, Taylor RS, Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology. 2010;117(7):1300–1305.e7. doi:10.1016/j.ophtha.2010.01.039.
   PubMed Web of Science ®Google Scholar
• Altan S, Sağsöz H, Oğurtan Z. Topical dimethyl sulfoxide inhibits corneal neovascularization and stimulates corneal repair in rabbits following acid burn. Biotech Histochem. 2017;92(8):619–636. doi:10.1080/10520295.2017.1371333.
   PubMed Web of Science ®Google Scholar
• Sharif Z, Sharif W. Corneal neovascularization: updates on pathophysiology, investigations & management. Rom J Ophthalmol. 2019;63(1):15–22.
   PubMedGoogle Scholar
• Chang JH, Garg NK, Lunde E, Han KY, Jain S, Azar DT. Corneal neovascularization: an anti-VEGF therapy review. Surv Ophthalmol. 2012;57(5):415–429. doi:10.1016/j.survophthal.2012.01.007.
   PubMed Web of Science ®Google Scholar
• Hosseini H, Nejabat M. A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med Hypotheses. 2007;68(4):799–801. doi:10.1016/j.mehy.2006.06.063.
   PubMed Web of Science ®Google Scholar
• Reck M, Heigener D, Reinmuth N. Nintedanib for the treatment of patients with advanced non-small-cell lung cancer. Expert Rev Clin Pharmacol. 2014;7(5):579–590. doi:10.1586/17512433.2014.945430.
   PubMed Web of Science ®Google Scholar
• Gong Y, Wu GH, Zhang LY, Zhang Z, Liao YH, Liu XT. Effect of nintedanib thermo-sensitive hydrogel on neovascularization in alkali burn rat model. Int J Ophthalmol. 2020;13(6):879–885. doi:10.18240/ijo.2020.06.04.
   PubMed Web of Science ®Google Scholar
• Lee JE, Kim MG, Jang YL, Lee MS, Kim NW, Yin Y, Lee JH, Lim SY, Park JW, Kim J, et al. Self-assembled PEGylated albumin nanoparticles (SPAN) as a platform for cancer chemotherapy and imaging. Drug Deliv. 2018;25(1):1570–1578. doi:10.1080/10717544.2018.1489430.
   PubMed Web of Science ®Google Scholar
• Zhou HY, Jiang LJ, Cao PP, Li JB, Chen XG. Glycerophosphate-based chitosan thermosensitive hydrogels and their biomedical applications. Carbohydr Polym. 2015;117:524–536. doi:10.1016/j.carbpol.2014.09.094.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Chen J, Li Y, Huang J, Huang Z, Huang Y, Pan X, Wu C. Thermo-sensitive gel in glaucoma therapy for enhanced bioavailability: In vitro characterization, in vivo pharmacokinetics and pharmacodynamics study. Life Sci. 2018;212:80–86. doi:10.1016/j.lfs.2018.09.050.
   PubMed Web of Science ®Google Scholar
• Fang G, Yang X, Wang Q, Zhang A, Tang B. Hydrogels-based ophthalmic drug delivery systems for treatment of ocular diseases. Mater Sci Eng C Mater Biol Appl. 2021;127:112212. doi:10.1016/j.msec.2021.112212.
   PubMed Web of Science ®Google Scholar
• Otero-Espinar FJ, Fernández-Ferreiro A, González-Barcia M, Blanco-Méndez J, Luzardo A. Stimuli sensitive ocular drug delivery systems - ScienceDirect. Drug Targeting and Stimuli Sensitive Drug Delivery Systems. 2018;6:211–270. doi:10.1016/b978-0-12-813689-8.00006-9.
   Google Scholar
• Karska-Basta I, Pociej-Marciak W, Chrząszcz M, Kubicka-Trząska A, Dębicka-Kumela M, Gawęcki M, Romanowska-Dixon B, Sanak M. Imbalance in the Levels of Angiogenic Factors in Patients with Acute and Chronic Central Serous Chorioretinopathy. JCM. 2021;10(5):1087. doi:10.3390/jcm10051087.
   Web of Science ®Google Scholar
• Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res. 2008;27(4):331–371. doi:10.1016/j.preteyeres.2008.05.001.
   PubMed Web of Science ®Google Scholar
• Jin L, Zhang Y, Liang W, Lu X, Piri N, Wang W, Kaplan HJ, Dean DC, Zhang L, Liu Y. Zeb1 promotes corneal neovascularization by regulation of vascular endothelial cell proliferation. Commun Biol. 2020;3(1):349. doi:10.1038/s42003-020-1069-z.
   PubMed Web of Science ®Google Scholar
• Campochiaro PA. Ocular neovascularisation and excessive vascular permeability. Expert Opin Biol Ther. 2004;4(9):1395–1402. doi:10.1517/14712598.4.9.1395.
   PubMed Web of Science ®Google Scholar
• Krizova D, Vokrojova M, Liehneova K, Studeny P. Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab. J Ophthalmol. 2014;2014:178132. doi:10.1155/2014/178132.
   PubMed Web of Science ®Google Scholar
• Mohan RR, Tovey JC, Sharma A, Schultz GS, Cowden JW, Tandon A. Targeted decorin gene therapy delivered with adeno-associated virus effectively retards corneal neovascularization in vivo. PLoS One. 2011;6(10):e26432. doi:10.1371/journal.pone.0026432.
   PubMed Web of Science ®Google Scholar
• Haber A, Polania-Baron EJ, Bolaños-Jimenez R, Navas A, Graue Hernandez EO, Garfias Y. Analysis of CCR3 expression in corneal neovascularization in a murine model and human corneas. Exp Eye Res. 2020;197:108076. doi:10.1016/j.exer.2020.108076.
   PubMed Web of Science ®Google Scholar
• Chau FY, Wallace D, Vajaranant T, Herndon L, Maumenee I. Osteogenesis Imperfecta and the Eye. Osteogenesis Imperfecta. 2014;31:289–303. doi:10.1016/B978-0-12-397165-4.00031-9.
   Google Scholar
• Campa C, Costagliola C, Incorvaia C, Sheridan C, Semeraro F, De Nadai K, Sebastiani A, Parmeggiani F. Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications. Mediators Inflamm. 2010;2010:1–14. doi:10.1155/2010/546826.
   Web of Science ®Google Scholar
• Al-Husainy S, Stavrou P, Hope-Ross MW. Alkali injury complicated by choroidal neovascularisation. Eye (Lond)). 2000;14(Pt 6):904–905. doi:10.1038/eye.2000.247.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Invernizzi A, Singh RB, Foulsham W, Aggarwal K, Handa S, Agrawal R, Pavesio C, Gupta V. An update on inflammatory choroidal neovascularization: epidemiology, multimodal imaging, and management. J Ophthalmic Inflamm Infect. 2018;8(1):13. doi:10.1186/s12348-018-0155-6.
   PubMed Web of Science ®Google Scholar
• Wollin L, Maillet I, Quesniaux V, Holweg A, Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. 2014;349(2):209–220. doi:10.1124/jpet.113.208223.
   PubMed Web of Science ®Google Scholar
• Kataria J, Kerr J, Lourenssen SR, Blennerhassett MG. Nintedanib regulates intestinal smooth muscle hyperplasia and phenotype in vitro and in TNBS colitis in vivo. Sci Rep. 2022;12(1):10275. doi:10.1038/s41598-022-14491-5.
   PubMed Web of Science ®Google Scholar
• Lee J, Rhee CK, Lee JH, Yoon HJ, Kim IK, Hur J, Kang JY, Yoon HK, Lee SY, Kim YK. Effect of nintedanib on airway inflammation in a mouse model of acute asthma. J Asthma. 2020;57(1):11–20. doi:10.1080/02770903.2018.1544641.
   PubMed Web of Science ®Google Scholar
• Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008;68(12):4774–4782. doi:10.1158/0008-5472.CAN-07-6307.
   PubMed Web of Science ®Google Scholar
• Zeinali S, Bichsel CA, Hobi N, Funke M, Marti TM, Schmid RA, Guenat OT, Geiser T. Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro. Angiogenesis. 2018;21(4):861–871. doi:10.1007/s10456-018-9631-8.
   PubMed Web of Science ®Google Scholar